Gregor Verhoef
About
In The Last Decade
Gregor Verhoef
186 papers receiving 9.2k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Pathology and Forensic Medicine 3.5k
- Hematology 3.1k
- Oncology 3.0k
- Genetics 2.3k
- Molecular Biology 2.2k
Countries citing papers authored by Gregor Verhoef
This map shows the geographic impact of Gregor Verhoef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregor Verhoef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregor Verhoef more than expected).
Fields of papers citing papers by Gregor Verhoef
This network shows the impact of papers produced by Gregor Verhoef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregor Verhoef. The network helps show where Gregor Verhoef may publish in the future.
Co-authorship network of co-authors of Gregor Verhoef
This figure shows the co-authorship network connecting the top 25 collaborators of Gregor Verhoef. A scholar is included among the top collaborators of Gregor Verhoef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregor Verhoef. Gregor Verhoef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 18 | |
| 3 | 2 | |
| 4 | Real-world data from 54 Belgian patients from the ponatinib named patient programme (NPP) | 1 |
| 5 | Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study | 1 |
| 6 | 119 | |
| 7 | 14 | |
| 8 | 255 | |
| 9 | Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma | 2 |
| 10 | A european observational study of dasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: forte study (ca180-211) | 1 |
| 11 | Primary Central Nervous System Post-Transplatation Lymphoproliferative Disorder | 1 |
| 12 | 121 | |
| 13 | Rituximab therapy for immune-mediated hematological disorders: A Belgian multi-center project | 2 |
| 14 | Refining the classification of low risk MDS: Retrospective analysis of cytomorphological and histological variables in 138 patients | 2 |
| 15 | Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML | 2 |
| 16 | A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) | 2 |
| 17 | Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL). | 3 |
| 18 | Intensive non-myeloablative chemotherapy can induce GvHD and complete remission in patients with AML/MDS relapsing after allo-BMT | 1 |
| 19 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) fails to improve outcome in invasive fungal infections in neutropenic cancer patients | 1 |
| 20 | Chromosomal gains and losses in marginal zone B-cell lymphoma detected by comparative genomic hybridization | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.